Transition Therapeutics in-licenses muscle drug candidate from Lilly

11 May 2015

The Canadian subsidiary of Ireland-headquartered Transition Therapeutics (Nasdaq: TTHL) has in-licensed exclusive worldwide rights to TT701, a novel small-molecule drug candidate from US pharma major Eli Lilly (NYSE: LLY).

TT701 is a selective androgen receptor modulator that has been shown in a Phase II study to significantly increase lean body mass and a measurement of muscle strength in male subjects. This completed 12-week, Phase II study of 350 subjects also demonstrated additional beneficial effects, including significant fat mass reduction with no significant change in prostate specific antigen (PSA) levels. Transition is evaluating multiple development paths for TT701, including as a new therapeutic option for patients with androgen deficiency. The company is engaged with potential collaborators to rapidly commence a Phase II clinical study.

Potential $100 million deal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK